Daniel r. Kuritzkes - Infectious Diseases

Author Information

Daniel R. Kuritzkes is a distinguished researcher affiliated with the Division of Infectious Diseases at Brigham and Women's Hospital and Harvard Medical School, located in Boston, MA. His work primarily focuses on the field of infectious diseases, contributing significantly to advancements in understanding and managing conditions such as HIV and COVID-19.

Research Contributions

Daniel R. Kuritzkes has made substantial contributions to the field of infectious diseases, with a strong focus on HIV and COVID-19. His recent research includes exploring the impact of tamoxifen on HIV expression in women, clinical management strategies for COVID-19 patients in the U.S., and advancements in entry inhibitors for HIV treatment. Additionally, he has examined the effectiveness of antiretroviral therapies in various settings and the implications of immune-related adverse events with anti-PD-1 inhibitors in people living with HIV. His studies on treatments like nirmatrelvir–ritonavir and remdesivir for COVID-19 further underscore his role in addressing contemporary infectious disease challenges.

Aliases

Daniel R. Kuritzkes is also known by several aliases in the academic community, including D. R. Kuritzkes, Dr Kuritzkes, Dan Kuritzkes, and other variations of his name. These aliases are often used in publications and citations.

Publication and Citation Metrics

Metric	Value
Total Citation Count	29,609
H-index	90
Total Paper Count	486

Publications:

Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial).

DOI: 10.1093/cid/ciac136

Year: 2022

Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States

DOI: 10.1093/ofid/ofab498

Year: 2022

Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV.

DOI: 10.1111/hiv.13288

Year: 2022

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions

DOI: 10.7326/M22-0281

Year: 2022

Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa.

DOI: 10.1111/hiv.13231

Year: 2022

Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV

DOI: 10.1097/QAI.0000000000002716

Year: 2021

38. Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality

DOI: 10.1093/ofid/ofab466.038

Year: 2021

Bamlanivimab for Prevention of COVID-19.

DOI: 10.1001/jama.2021.7515

Year: 2021

Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort.

DOI: 10.1093/cid/ciab875

Year: 2021

Viral Reservoir in Early-Treated HIV-Infected Children and Markers for Sustained Viral Suppression.

DOI: 10.1093/cid/ciab143

Year: 2021

How to Interpret Imaging Results?

What are the Treatment Options for Fatigue in Infectious Diseases?

What is Ebola Virus?

What Is the Role of the Immune System in Fighting Infectious Diseases?

What is the Scope of Infectious Diseases?

What is Disease Eradication?

What Role do Vaccines Play in Reducing Mortality?

What are the treatment options for Plasmodium falciparum malaria?

What Is the Future of Malaria Research?

How do Structural Proteins Aid in Viral Assembly?

Partnered Content Networks

Relevant Topics